Newsroom | 5819 results

MANHASSET, N.Y.--(BUSINESS WIRE)--For centuries, stopping severe bleeding has relied on physical pressure or surgery. A pioneering study from Northwell Health’s Feinstein Institutes for Medical Research now demonstrates that a small, wearable device placed on the ear can activate the vagus nerve and accelerate clot formation, offering new hope against life-threatening hemorrhage.This first-in-human mechanistic study, recently published in the journal Bioelectronic Medicine – an open-access journ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics Presents Exploratory Biomarker Data at AAIC 2026 Supporting Coordinated Modulation of Lipid Transport and Myelination Pathways...

SAN FRANCISCO--(BUSINESS WIRE)--Universal Brain Receives FDA 510(k) Clearance for Rapid Brain-Function Measurement Platform for Psychiatry...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline1 on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 24 of the LTE, approxim...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome, a rare, severe and lifelong neurological disorder. Dravet syndrome typically begins in infancy and is associated with prolonged seizures, developmental delays, cognitive impairments and an increased risk of sudden death. “The first participa...

RALEIGH, N.C.--(BUSINESS WIRE)--CaringAI, a healthcare technology company building an AI-powered voice agent platform for patient engagement, cognitive assessment, and dementia care, today announced research presented at the Alzheimer's Association International Conference (AAIC) 2026— the world's largest dementia research conference— in London. The study evaluates clinician agreement with CaringAI Listen, the company's telephone-based AI cognitive assessment platform, in real-world primary car...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachu...

BOSTON--(BUSINESS WIRE)--ZETA SURGICAL today announced that its Zeta TMS Robotic System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The device is classified as a Class II stereotaxic instrument under 21 CFR 882.4560 and product codes SGE and QFF (K261471). Transcranial magnetic stimulation, or TMS, is a non-invasive therapy used primarily for treatment-resistant depression, which affects approximately one-third of patients with major depressive disorder. TMS...

TEL AVIV, Israel, und ZUG, Schweiz--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, eine Tochtergesellschaft von Teva Pharmaceutical Industries Ltd. (NYSE und TASE: TEVA), und Polpharma Biologics International AG gaben heute den Abschluss einer globalen Lizenzvereinbarung bekannt, die Teva nach der aufsichtsrechtlichen Zulassung die exklusiven Rechte zur Vermarktung beider Darreichungsformen des von Polpharma Biologics entwickelten Biosimilar-Kandidaten für Ocrevus®1 (Ocrelizumab) ein...